Attovia Therapeutics, Inc. (ATTO) shareholders
Close on Nov 17, 2026Market cap $678.38MP/E –Yield –
Ownership
Who owns Attovia Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Frazier Life Sciences XI, L.P. Joint filing with Fhmls Xi, L.P. (13.50%), Fhmls Xi, L.L.C. (13.50%) | 6,154,213 | 13.50% | 13D (active) | Aug 6, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (7.45%), Deep Track Biotechnology Master Fund, Ltd. (7.45%) | 3,207,138 | 7.45% | 13G (passive) | Aug 5, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Tao Fu | President and CEO, Director | 333,268 | 0.73% | Oct 8, 2026 |
| Attovia Therapeutics, Inc. | President and CEO, Director | 449,371 | 0.98% | Aug 6, 2026 |
| Steven Chan | Chief Financial Officer | – | – | Oct 8, 2026 |
| Petter Veiby | Chief Scientific Officer | 104,951 | 0.23% | Aug 6, 2026 |
| Hubert Chen | Chief Medical Officer | 2,960 | 0.01% | Aug 6, 2026 |
| Zaneta Odrowaz | Chief Business Officer | 103,269 | 0.23% | Aug 6, 2026 |
| Colin Walsh | Director | 2,520,632 | 5.52% | Aug 28, 2026 |
| Angie You | Director | 52,852 | 0.12% | Aug 6, 2026 |
| Mitchell Gold | Director | – | – | Aug 6, 2026 |
| John W. Smither | Director | – | – | Aug 4, 2026 |
| Aaron Royston | Director | – | – | Aug 4, 2026 |
| James N. Topper | Director | – | – | Aug 4, 2026 |
| West Street Life Sciences I, L.P. | – | – | – | Aug 28, 2026 |
| Wsls Emp Offshore Investments, L.P. | – | – | – | Aug 28, 2026 |
| Wsls Offshore Investments, Slp | – | – | – | Aug 28, 2026 |
| Broad Street Principal Investments, L.L.C. | – | – | – | Aug 28, 2026 |
| Sachs Group Inc Goldman | – | – | – | Aug 28, 2026 |
| Goldman Sachs Asset Management, L.P. | – | 3,020,632 | 6.62% | Aug 28, 2026 |
| Wsls Emp Onshore Investments, L.P. | – | – | – | Aug 28, 2026 |
| Sachs & Co. Llc Goldman | – | 2,042,134 | 4.47% | Aug 28, 2026 |
| David Kroin | 10% owner | – | – | Aug 10, 2026 |
| Deep Track Capital, LP | 10% owner | – | – | Aug 10, 2026 |
| venBio Global Strategic Fund IV, L.P. | 10% owner | 3,799,015 | 8.32% | Aug 10, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 10% owner | 1,957,138 | 4.29% | Aug 10, 2026 |
| Sanofi | 10% owner | 1,082,855 | 2.37% | Aug 7, 2026 |
| Redmile Biopharma Investments III, L.P. | 10% owner | – | – | Aug 7, 2026 |
| Redmile Group, LLC | 10% owner | – | – | Aug 7, 2026 |
| Jeremy Green | 10% owner | 2,948,562 | 6.46% | Aug 7, 2026 |
| Fhmls Xi, L.P. | 10% owner | 1,824,541 | 4.00% | Aug 6, 2026 |
| Frazier Life Sciences XI, L.P. | 10% owner | – | – | Aug 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Colin Walsh Director | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Colin Walsh Director | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| Colin Walsh Director | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Goldman Sachs Asset Management, L.P. – | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Goldman Sachs Asset Management, L.P. – | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Goldman Sachs Asset Management, L.P. – | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| Sachs & Co. Llc Goldman – | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| Sachs & Co. Llc Goldman – | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Sachs & Co. Llc Goldman – | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Colin Walsh Director | Aug 6, 2026 | Buy | +500,000 | $17.00 | $8.50M | 3,020,632 |
| Colin Walsh Director | Aug 6, 2026 | Conversion | +478,498 | – | – | 2,520,632 |
| Colin Walsh Director | Aug 6, 2026 | Conversion | +1,957,134 | – | – | 2,042,134 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Conversion | +665,147 | – | – | 3,799,015 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Conversion | +2,311,870 | – | – | 2,311,870 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Conversion | +821,998 | – | – | 3,133,868 |
| venBio Global Strategic Fund IV, L.P. 10% owner | Aug 6, 2026 | Buy | +382,352 | $17.00 | $6.50M | 4,181,367 |
| Deep Track Biotechnology Master Fund, Ltd. 10% owner | Aug 6, 2026 | Conversion | +1,957,138 | – | – | 1,957,138 |
| Sanofi 10% owner | Aug 6, 2026 | Buy | +300,000 | $17.00 | $5.10M | 1,082,855 |
| Sanofi 10% owner | Aug 6, 2026 | Conversion | +782,855 | – | – | 782,855 |
| Jeremy Green 10% owner | Aug 6, 2026 | Buy | +400,000 | $17.00 | $6.80M | 1,182,854 |
| Jeremy Green 10% owner | Aug 6, 2026 | Conversion | +782,854 | – | – | 782,854 |
| Jeremy Green 10% owner | Aug 6, 2026 | Buy | +200,000 | $17.00 | $3.40M | 982,854 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +1,749,192 | – | – | 1,824,541 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +1,590,175 | – | – | 3,414,716 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +1,189,940 | – | – | 4,604,656 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Conversion | +961,322 | – | – | 5,565,978 |
| Fhmls Xi, L.P. 10% owner | Aug 6, 2026 | Buy | +588,235 | $17.00 | $10.00M | 6,154,213 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −76,418 | $21.04 | $1.61M | 0 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −6,763 | $21.61 | $146.15K | 55,611 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −100 | $21.99 | $2.20K | 62,374 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,163 | $22.19 | $25.81K | 62,474 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −700 | $22.07 | $15.45K | 63,637 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −200 | $22.05 | $4.41K | 64,337 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −443 | $21.78 | $9.65K | 64,537 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −300 | $20.84 | $6.25K | 64,980 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,040 | $22.05 | $22.93K | 65,280 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,180 | $21.84 | $25.77K | 66,320 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −400 | $22.02 | $8.81K | 67,500 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −6,970 | $22.03 | $153.55K | 67,900 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −672 | $22.02 | $14.80K | 74,870 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −753 | $21.97 | $16.54K | 75,542 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −100 | $22.11 | $2.21K | 76,295 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −480 | $21.55 | $10.34K | 76,395 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −3,402 | $22.02 | $74.91K | 77,075 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,556 | $22.06 | $34.33K | 80,477 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −200 | $22.05 | $4.41K | 82,033 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −1,332 | $22.03 | $29.34K | 82,233 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −447 | $21.87 | $9.78K | 83,565 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −988 | $22.03 | $21.77K | 84,012 |
| Colin Walsh Director | Aug 5, 2026 | Buy | +85,000 | $21.00 | $1.79M | 85,000 |
| Colin Walsh Director | Aug 5, 2026 | Sale | −200 | $22.10 | $4.42K | 76,875 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −100 | $22.11 | $2.21K | 76,295 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −480 | $21.55 | $10.34K | 76,395 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −200 | $22.10 | $4.42K | 76,875 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −3,402 | $22.02 | $74.91K | 77,075 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −1,556 | $22.06 | $34.33K | 80,477 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −200 | $22.05 | $4.41K | 82,033 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −1,332 | $22.03 | $29.34K | 82,233 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −447 | $21.87 | $9.78K | 83,565 |
| Goldman Sachs Asset Management, L.P. – | Aug 5, 2026 | Sale | −988 | $22.03 | $21.77K | 84,012 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Attovia Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 51,556 shares on Sep 15, 2026 over the last 90 days.
See a number that looks wrong?